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Abstract 
 
Introduction 
Patients with metastatic hormone-sensitive prostate cancer (mHSPC) have 
never received androgen deprivation therapy (ADT) before, meaning that 
they are sensitive to ADT. Enzalutamide (Xtandi®) is an androgen receptor 
inhibitor, which is neither approved by the European Medicines Agency 
(EMA) nor by the US Food and Drug Administration (FDA) as an addition to 
first-line treatment of patients with mHSPC. 
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, Embase, Ovid Medline, PubMed, Internet sites and contacting the 
manufacturer, resulting in 137 references overall. A quality assessment was 
conducted to assess the risk of bias at the study level based on the EUnetHTA 
internal validity for randomised controlled trials. To evaluate the magnitude 
of “meaningful clinical benefit” that can be expected from a new anti-cancer 
treatment, the Magnitude of Clinical Benefit Scale developed by the Europe-
an Society for Medical Oncology (ESMO-MCBS) was used. 
Results from the ENZAMET trial 
The aim of the ENZAMET trial was to compare the efficacy and safety of add-
ing enzalutamide to testosterone suppression. Since the trial is currently on-
going, the presented data is the first interim analysis. Overall survival (OS) 
was statistically significantly prolonged with enzalutamide: the hazard ratio 
(HR) was 0.67; however, the median OS time was not estimable in either 
treatment group. The benefit in favour of enzalutamide has also been ob-
served for the following secondary endpoints: prostate-specific antigen pro-
gression-free survival (PSA PFS, HR 0.39) and clinical PFS (HR 0.40). For two 
of the pre-specified endpoints, health-related quality of life (HRQoL) and 
health outcomes relative to costs, no results are available yet. According to 
the authors, these results will be reported separately. Among patients of the 
enzalutamide group who have received early docetaxel, PFS was prolonged 
whilst OS was not. The incidence of serious adverse events (AEs) was higher 
among patients of the enzalutamide group (42%) than in patients receiving 
standard care (34%). In patients of the enzalutamide group who received 
additional early docetaxel treatment, toxic effects occurred more often than 
in patients of the control group. Seizures occurred in seven patients receiv-
ing enzalutamide and in none of standard-care group patients. 
 
Conclusion 
Recently published results from the ENZAMET trial indicate that patients 
with mHSPC benefit from the addition of enzalutamide to standard first-line 
treatment in terms of OS and PSA PFS. However, the administration of en-
zalutamide was associated with a higher rate of serious AEs as compared to 
standard care. Due to the ongoing status of the trial, mature final and long-
term data are lacking. However, due to the nature of the open-label study de-
sign, a high risk of bias is existent and will remain even with mature data. 
Since final OS data and HRQoL data are not available yet, the clinical benefit 
for affected patients cannot be assessed. More mature data, acquired over a 
longer treatment duration, are required to prove the present results. 
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1 Research questions 
The HTA Core Model® for Rapid Relative Effectiveness Assessment of Phar-
maceuticals was used for structuring this report [1]. The Model organises 
HTA information according to pre-defined generic research questions. Based 
on these generic questions, the following research questions were answered 
in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is enzalutamide and the comparator(s)? 
A0022 Who manufactures enzalutamide? 
A0007 What is the target population in this assessment? 
A0020 For which indications has enzalutamide received marketing authorisation? 
Health problem and current use 
A0002 What is prostate cancer? 
A0004 What is the natural course of prostate cancer? 
A0006 What are the consequences of prostate cancer? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of prostate cancer? 
A0003 What are the known risk factors for prostate cancer? 
A0024 
How is prostate cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is prostate cancer currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of enzalutamide on mortality? 
D0006 How does enzalutamide affect progression (or recurrence) of prostate cancer? 
D0005 
How does enzalutamide affect symptoms and findings (severity, frequency) of prostate 
cancer? 
D0011 What is the effect of enzalutamide on patients ̕ body functions? 
D0012 What is the effect of enzalutamide on generic health-related quality of life? 
D0013 What is the effect of enzalutamide on disease-specific quality of life? 
Safety 
C0008 How safe is enzalutamide in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying enzalutamide? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of enzalutamide? 
A0021 What is the reimbursement status of enzalutamide? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Enzalutamide/Xtandi®/L02BB04  
 
B0001: What is enzalutamide and the comparator(s)? 
Enzalutamide (Xtandi®) is an androgen receptor inhibitor that blocks sever-
al steps in the androgen receptor signalling pathway. It blocks androgen 
binding to the respective receptors, thereby inhibiting nuclear translocation 
of activated receptors and the association of the activated androgen receptor 
with deoxyribonucleic acid (DNA). Thus, enzalutamide decreases the growth 
of prostate cancer cells and can induce the death of cancer cells and tumour 
regression. These mechanisms of action also work in the setting of androgen 
receptor overexpression and in prostate cancer cells that are resistant to an-
ti-androgens [2, 3]. 
For the treatment of patients with non-metastatic or metastatic castration-
resistant prostate cancer (CRPC), the recommended dose of enzalutamide is 
160 mg (4x40 mg soft capsules), administered as a single oral daily dose. 
The soft capsules can be taken with or without food and should be swal-
lowed whole; they should not be chewed, dissolved or opened. During en-
zalutamide treatment, the administration of a luteinising hormone-releasing 
hormone (LHRH) analogue should be continued if patients are not surgically 
castrated. In the case of grade ≥3 toxicities or intolerable adverse reactions, 
the dosing of enzalutamide should be withheld for one week or until the 
symptoms improve to grade ≥2. If warranted, the administration of enzalu-
tamide – at the same or a reduced dose (120 mg or 80 mg) – can be contin-
ued. The concomitant use of strong CYP2C8 inhibitors should be avoided. 
Special warnings and precautions for use are listed below (see C0005) [2, 3]. 
Participants of the ENZAMET trial who were assigned to the control group 
received a conventional non-steroidal anti-androgen (NSAA), including bi-
calutamide, nilutamide or flutamide [4].  
 
A0022: Who manufactures enzalutamide? 
Astellas Pharma Europe B.V. 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Enzalutamide (Xtandi®) is indicated in addition to standard first-line ther-
apy in patients with metastatic hormone-sensitive prostate cancer 
(mHSPC). 
 
androgen receptor 
inhibitor  
 
CRPC: 160 mg 
enzalutamide orally 
once daily 
 
 
 
concomitant use of 
LHRH analogue  
comparator: standard 
NSAA 
added to standard first-
line treatment in men 
with mHSPC 
Enzalutamide in addition to standard first-line therapy in men with mHSPC 
LBI-HTA | 2019 9 
4 Current regulatory status 
A0020: For which indications has enzalutamide received marketing authorisa-
tion? 
To date, enzalutamide (Xtandi®) is neither approved by the European Medi-
cines Agency (EMA) nor by the U.S. Food and Drug Administration (FDA) for 
the administration with standard first-line therapy in men with mHSPC. 
In Europe, the EMA granted marketing authorisation for enzalutamide for 
the following indications [3]: 
 The treatment of adult men with high-risk non-metastatic CRPC;  
 The treatment of adult men with metastatic CRPC who are asymp-
tomatic or mildly symptomatic after failure of androgen deprivation 
therapy (ADT) in whom chemotherapy is not yet clinically indicat-
ed;  
 The treatment of adult men with metastatic CRPC whose disease 
has progressed on or after docetaxel therapy. 
The FDA approved enzalutamide for the treatment of patients with CRPC [2]. 
 
 
5 Burden of disease 
A0002: What is prostate cancer? 
Prostate cancer develops in the tissue of the prostate gland. Patients with 
mHSPC have metastatic prostate cancer and have never received ADT before, 
meaning that these patients are sensitive to ADT [5]. 
 
A0004: What is the natural course of prostate cancer? 
Three stages of prostate cancer can be distinguished: localised, locally-
advanced and advanced prostatic cancer [6]. According to data from the US 
population, 77% of prostate cancer cases are diagnosed at a local stage (con-
fined to the primary site), 13% are diagnosed at a regional stage (spread to 
regional lymph nodes) and 6% of cases are diagnosed at a distant stage, 
when the disease has already metastasised. 4% of prostate cancer cases re-
main unstaged [7]. 
In Austria, the relative survival rate following diagnosis in patients with 
prostate cancer (2009–2013) is 95.6% at one year, 93.1% at three years and 
91.5% at five years. In 2016, the age-standardised mortality rate of the Eu-
ropean Standard Population (2013) was 38.7 per 100,000 men per year; 
1,225 men died from prostate cancer. At the end of the year 2016, 63,415 
men diagnosed with prostate cancer were alive; more than 40% of the af-
fected patients (25,572 men) were diagnosed at least ten years ago [8]. 
 
 
FDA and EMA: currently 
not licensed for the 
assessed indication 
 
EMA-approved 
indications 
approved by FDA for 
CRPC treatment 
mHSPC patients are 
sensitive to ADT 
 
77% of prostate cancer 
cases are diagnosed at 
the local stage 
Austria: 5-year relative 
survival rate of 91.5% 
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A0006: What are the consequences of prostate cancer for the society? 
A0023: How many people belong to the target population? 
In Austria, 5,245 men were newly diagnosed with prostate cancer in 2016; 
the age-standardised incidence rate of the European Standard Population 
(2013) is 138.3 per 100,000 men per year (2016). 
According to data from the US1, from 2004–2012 mHSPC is estimated to con-
stitute approximately 5% of prostate cancer cases [5]. Prostate cancer is most 
frequently diagnosed among men between the ages of 65 and 74 years; the 
median age at diagnosis is 66 years [7]. A study of current and forecast inci-
dence trends of metastatic prostate cancer in 25,033 men aged 45 to 94 years 
who were diagnosed with metastatic prostate cancer from 2004 to 2014, 
showed a median age at diagnosis of 71 years [9]. 
 
A0005: What are the symptoms and the burden of prostate cancer? 
Most cases of prostate cancer are diagnosed at the local stage when patients 
are asymptomatic. Patients rarely present with non-specific urinary symp-
toms, including haematuria or haematospermia, that are usually associated 
with non-malignant conditions [10]. 
Patients with metastatic disease at the time of diagnosis may present with 
bone pain; other symptoms are weight loss, weakness or pain caused by spi-
nal cord compression or due to pathologic fractures, fatigue due to anaemia, 
renal or urinary symptoms (haematuria, inability to void, incontinence), as 
well as symptoms that are associated with chronic renal failure. A clinical 
sign that can be associated with prostate cancer is an elevation of PSA on la-
boratory testing. However, PSA is not specific for malignancy, since an eleva-
tion may also be caused by a number of benign conditions. Although PSA is 
not specific for prostate cancer, the measurement of the PSA level is the most 
commonly used and most valuable test to detect prostate cancer at an early 
stage. Further clinical signs that may indicate the presence of prostate can-
cer are abnormal findings on the digital rectal examination (DRE). A DRE 
may enable the detection of prostate nodules, indurations or asymmetries 
potentially associated with prostate cancer. However, only tumours that are 
localised in the posterior and lateral aspects of the prostate gland can be de-
tected by a DRE; tumours in other parts of the gland are not reachable or not 
palpable [11]. 
 
A0003: What are the known risk factors for prostate cancer? 
The risk for the development of clinically significant prostate cancer is relat-
ed to the following factors [11-15]:  
 Age: Increasing age is the most important risk factor for the devel-
opment of prostate cancer. The disease is rare in men younger than 
40 years, but its incidence increases progressively thereafter.  
 Ethnicity: African Americans have a higher risk of developing pros-
tate cancer and the disease occurs at an earlier stage. Furthermore, 
prostate cancer is associated with a more aggressive clinical course 
in African Americans than in other ethnic groups.  
                                                                        
1 There is no data available regarding incidence rates of mHSPC in Europe. 
Austria: incidence rate 
of 138.3/100,000 
men/year 
mHSPC constitutes 
approx. 5% of prostate 
cancer cases 
 
median age at diagnosis 
of metastatic prostate 
cancer: 71 years 
mostly diagnosed at 
asymptomatic,  
local stage 
symptoms of  
metastatic disease 
increasing age 
African Americans: 
higher risk 
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 Family history: There is a strong inherited component regarding 
the development of prostate cancer; a family history of prostate 
cancer and other cancers can increase the risk. There are genetic 
factors (especially germline mutations in DNA repair genes, e.g., 
BRCA2) which seem to play an important role in the development 
of certain types of prostate cancer and may be associated with a 
more aggressive course of the disease. Genetic risk assessment 
should be conducted, including a detailed personal and family can-
cer history in first- and second-degree relatives (type of cancer, age 
at diagnosis and ancestry). If a suggestive family history is estab-
lished, patients should be referred for genetic counselling, and ge-
netic testing should be conducted.  
 PSA level: The likelihood of the presence of prostate cancer increas-
es with a more elevated PSA value. Although PSA is consistently ex-
pressed in almost all prostate cancers, high-grade prostate cancer 
can occur in men with a “normal” PSA level.  
 Free/total PSA ratio (f/t PSA): The percentage of f/t PSA may be 
used for a higher sensitivity of cancer detection in patients with a 
total PSA within the normal range (<4 ng/ml) and to increase the 
specificity to detect prostate cancer when total PSA is in the “grey 
zone” (4.1 to 10 ng/ml).  
 Findings on DRE, including prostate nodules, indurations or asym-
metries.  
 Whether a prior vasectomy increases risk for prostate cancer is 
controversial. 
 Other factors, including diet, hormone levels and obesity, may have 
some effect on the incidence of prostate cancer; however, the role of 
these factors appears to be limited. 
 
A0024: How is prostate cancer currently diagnosed according to published 
guidelines and in practice? 
An elevation in PSA levels or an abnormality on DRE can be a signs of pros-
tate cancer that warrant additional evaluation. There is no consistent PSA 
threshold for defining an abnormal PSA value [11]. 
The final diagnosis of prostate cancer is based on the histology of tissue 
which is obtained by conducting a core needle biopsy of the prostate. If the 
results indicate the presence of prostate cancer, a Gleason grade (which cor-
relates closely with clinical behaviour) is generated by using architectural 
features of the obtained cells. The Gleason grade for the two most prevalent 
differentiation patterns is used to create the Gleason score and is now used 
in the new grading (grade group) system; the latter provides a more accu-
rate risk stratification. Due to the fact that sampling techniques which have a 
substantial potential for missing malignant tissue are used for prostate biop-
sies, the possibility of the presence of prostate cancer cannot be ruled out by 
conducting a biopsy. In case the PSA level increases further, or findings on 
DRE or prostate imaging indicate prostate cancer, a repetition of the biopsy 
is warranted [11, 16]. 
strong inherited 
component 
elevated PSA level 
f/t PSA ratio 
suspicious findings on 
DRE 
controversial role of 
prior vasectomy  
 
other factors: limited 
role 
no consistent PSA 
threshold 
final diagnosis is based 
on histological 
examination 
 
 
grading system 
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According to the EAU-ESTRO-ESUR-SIOG2 Guidelines on Prostate Cancer 
[17], frequent post-treatment PSA surveillance leads to earlier detection of 
disease progression in non-metastatic CRPC. Approximately one-third of pa-
tients with a rising PSA develop bone metastases within two years. However, 
there is no evidence available demonstrating a benefit for immediate treat-
ment. A consensus statement by the Prostate Cancer Radiographic Assess-
ments for Detection of Advanced Recurrence (RADAR) group suggested the 
conduction of a bone scan and a CT when the PSA level has reached 2 ng/ml. 
If the results are negative, the imaging procedures should be repeated when 
the PSA has reached 5 ng/ml and then again after every doubling of the PSA 
level based on PSA measurement every three months for asymptomatic pa-
tients. If patients are symptomatic, they should undergo relevant examina-
tion. Bone scanning should be performed in symptomatic patients independ-
ent of the PSA level, Gleason score or clinical stage. The most widely used 
method for evaluating bone metastases in patients with prostate cancer is 
the 99mTc-bone scan [17]. 
Differential diagnosis should be considered for prostate cancer. Lower uri-
nary tract symptoms, including frequency, urgency, nocturia, and hesitancy, 
occur commonly among men and are usually related to benign conditions ra-
ther than to prostate cancer. An elevation of the PSA level can be caused by 
transient conditions, such as prostatitis or perineal trauma, and by persis-
tent causes such as benign prostate hyperplasia (BPH) [11]. 
 
 
6 Current treatment 
A0025: How is prostate cancer currently managed according to published 
guidelines and in practice? 
According to the European Association of Urology (EAU) – Updated Guide-
lines for mHSPC [18], it is strongly recommended to offer the following 
treatment options: 
 Surgical or medical castration (LHRH agonist or antagonist) as ADT; 
 Castration combined with chemotherapy (docetaxel) to all patients 
whose first presentation is M1 disease and who are fit enough for 
chemotherapy; 
 Castration combined with abiraterone acetate + prednisone to all 
patients whose first presentation is M1 disease and who are fit 
enough for the regimen; 
 Castration, with or without an anti-androgen, to patients unfit for a 
combination with docetaxel or abiraterone acetate + prednisone, or 
who are unwilling to consider it. 
According to the National Comprehensive Cancer Network (NCCN) guideline 
[19], options for the systemic therapy for castration-naïve disease (M1) in-
clude: 
                                                                        
2 EAU = European Association of Urology, ESTRO = European Society for Radiother-
apy & Oncology, ESUR = European Society of Urogenital Radiology, SIOG = Interna-
tional Society of Geriatric Oncology. 
EAU-ESTRO-ESUR-SIOG 
recommendations 
differential diagnosis 
EAU recommendations 
NCCN guidelines 
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 ADT and docetaxel 75 mg/m2 for six cycles (category 1 recommen-
dation, based upon high-level evidence), or 
 ADT and abiraterone with prednisone (category 1 recommenda-
tion, based upon high-level evidence), or 
 ADT and external beam radiotherapy (EBRT) to the primary tu-
mour for low-volume M1, or 
 ADT, or 
 ADT and abiraterone with methylprednisolone. 
 
 
7 Evidence 
A literature search was conducted on 15 July 2019 in four databases: the 
Cochrane Library, Embase, Ovid Medline and PubMed. Search terms were 
“enzalutamide”, “xtandi”, “L02BB04”, “prostate cancer”, “prostate neo-
plasms”, “metastatic”, “first-line” and “initial”. The manufacturer was also 
contacted and submitted five references (one of them had already been iden-
tified by systematic literature search). A manual search identified 30 addi-
tional references (web documents and journal articles, including all refer-
ences used in this report). 
Overall, 137 references were identified. Included in this reported are:  
 ENZAMET [4, 20, 21], a multinational, open-label, randomised 
phase III study evaluating the efficacy and safety of adding enzalu-
tamide to standard first-line therapy in men with mHSPC 
 ARCHES [22], a multinational, double-blind, randomised, placebo-
controlled phase III trial, aiming to assess the efficacy and safety of 
enzalutamide plus ADT in men with mHSPC. 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA inter-
nal validity for randomised controlled trials (RCTs) [23]. Evidence was as-
sessed based on the adequate generation of the randomisation sequence, al-
location concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 6 of the Appendix. 
The external validity of the ENZAMET trial was assessed using the EU-
netHTA guideline on the applicability of evidence in the context of a relative 
effectiveness assessment of pharmaceuticals, considering the following ele-
ments: population, intervention, comparator, outcomes and setting (see Ta-
ble 5) [24]. 
To evaluate the magnitude of “meaningful clinical benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [25]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [26]. Details of the magnitude of 
the clinically meaningful benefit scale are reported in Table 3. 
 
systematic literature 
search in 3 databases:  
107 hits 
 
manual search:  
30 additional references 
overall: 137 references 
included: 2 studies 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
applicability of  
study results 
magnitude of 
meaningful clinical 
benefit assessed based 
on ESMO-MCBS 
Horizon Scanning in Oncology 
14 LBI-HTA | 2019 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence and the amount of eligi-
ble patients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines to be a quality assurance method of scientific work. The 
final version and the policy recommendations are under full responsibility of 
the LBI-HTA. 
 
 
7.2 Clinical efficacy and safety –  
phase III studies 
The ENZAMET trial [4, 20, 21] is a multinational, multicentre (83 sites), 
open-label, randomised phase III trial aiming to determine the effects of add-
ing enzalutamide to first-line treatment in men with mHSPC. Between March 
2014 and March 2017, a total of 1,125 men who underwent randomisation 
were assigned in a 1:1 ratio to receive testosterone suppression plus either 
enzalutamide (n = 563) or standard care (n = 562). Randomisation was 
stratified according to the volume of disease (high/low), the planned use of 
early docetaxel (yes/no), the planned use of bone resorptive therapy 
(yes/no) and the score on the Adult Comorbidity Evaluation 27 (ACE-27, 0/1 
or 2/3) and trial site. Patients were eligible to participate in the ENZAMET 
trial if they had prostatic adenocarcinoma with metastases on computed to-
mography (CT), 99mTc-bone scan, or both, an Eastern Cooperative Oncology 
Group (ECOG) performance status of 2 or less, and adequate bone marrow, 
liver and renal function. Detailed inclusion and exclusion criteria can be 
found in Table 5. 
internal and external 
review  
quality assurance 
method 
ENZAMET: open-label, 
randomised phase III 
trial 
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Patients of both groups had a median age of 69 years, more than half of them 
were Australians; further patients were enrolled throughout Canada, Ire-
land, New Zealand, the United Kingdom and the United States. There is no in-
formation available regarding the percentage of participants who were of Af-
rican American descent. The percentage of patients who showed a high-
volume disease was similar in both groups: 52% (enzalutamide group) and 
53% (standard-care group). Visceral metastases were diagnosed in 11% of 
enzalutamide group patients and 12% of standard-care group patients; the 
median time since the diagnosis of metastasis was 1.9 months in patients of 
either group. More than half of the patients (60% in the enzalutamide group 
and 57% in the standard-care group) had a Gleason score of 8 to 10. 51% of 
enzalutamide group patients and 56% of standard-care group patients re-
ceived an anti-androgen therapy prior to the study treatment; 73% (enzalu-
tamide group) and 74% (standard-care group) were treated with a LHRH 
agonist or antagonist (LHRHa). Previous docetaxel was administered in 17% 
of enzalutamide group patients and 15% of standard-care group patients. In 
the enzalutamide group, 10% of patients had prior adjuvant ADT as com-
pared to 7% of patients in the standard-care group; 1% of patients in either 
group underwent bilateral orchiectomy. With 45% (enzalutamide group) 
and 44% (standard-care group), the planned use of docetaxel was balanced 
between the treatment groups. Detailed patient characteristics can be found 
in Table 5. 
Patients assigned to the enzalutamide group received enzalutamide at a total 
daily dose of 160 mg daily, provided as four orally administered 40 mg soft 
gelatine capsules. Patients of the standard-care group received a conven-
tional NSAA, i.e., bicalutamide 50 mg daily, nilutamide 150 mg daily, or 
flutamide 250 mg three times a day (cyproterone was not permitted). The 
type of NSAA was chosen at the discretion of the treating physician and drug 
administration was performed according to the respective product infor-
mation guide. 
Patients of both groups received a standard background therapy with an 
LHRHa or surgical castration; the choice between these two options was at 
the discretion of the treating clinician. LHRHa should be administered ac-
cording to the product information guide; options included, but were not re-
stricted to goserelin, leuprorelin, triptorelin, and degarelix. In case of surgi-
cal castration with bilateral orchiectomy (instead of LHRHa treatment), it 
had to be done less than twelve weeks before randomisation or within seven 
days after randomisation. Patients of both groups had the possibility to initi-
ate early treatment with docetaxel. If docetaxel was administered, the pa-
tients received 75 mg/m2 of body-surface area every three weeks for a max-
imum of six cycles (without prednisone or prednisolone). 65% of patients in 
the enzalutamide group and 76% of standard-care group patients received 
the full planned course of six cycles of docetaxel. Before randomisation, up to 
two cycles of docetaxel were permitted. Trial patients received the study 
treatment until the occurrence of clinical disease progression or prohibitive 
toxic effects. 
median age of 69 years 
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Overall survival (OS) was the primary endpoint of the ENZAMET trial, de-
fined as the interval from randomisation to death from any cause or to the 
date at which the patient was last known to be alive. PSA progression-free 
survival (PFS) was a secondary endpoint, measured as the interval from 
randomisation to the earliest event of PSA progression according to the cri-
teria of the Prostate Cancer Working Group 2 (a confirmed relative increase 
in the PSA level from the nadir value by ≥25% and by ≥2 ng/ml), clinical 
progression, death from any cause, or the last known date of follow-up with-
out PSA progression. Clinical progression, another secondary endpoint, was 
defined as the earliest sign of radiographic progression according to the cri-
teria of the Prostate Cancer Working Group 2 for bone lesions and the Re-
sponse Evaluation Criteria in Solid Tumours (RECIST version 1.1) for soft-
tissue lesions, the development of symptoms attributable to cancer progres-
sion or the initiation of another anti-cancer treatment for prostate cancer. 
Clinical efficacy data are presented in Table 1. Data with regard to adverse 
events (AEs) were collected during the treatment period and a final safety 
assessment was conducted 30 to 42 days after the termination of study 
treatment. AE data are presented in Table 2. The authors announced that tri-
al results regarding health-related quality of life (HRQoL), resource use and 
incremental cost-effectiveness are to be reported separately. 
The first interim analysis of OS was performed on 28 February 2019, after 
the occurrence of 235 deaths; the median follow-up time was 34 months. At 
three years, 62% of enzalutamide group patients and 34% of standard-care 
group patients were still receiving study treatment. 66% of patients treated 
with enzalutamide and 71% of patients who received standard care discon-
tinued the trial regimen due to disease progression or death. 
The ENZAMET trial is ongoing until December 2020 (estimated study com-
pletion date) [27]; the presented data is interim analysis data. 
 
 
7.2.1 Clinical efficacy 
D0001: What is the expected beneficial effect of enzalutamide on mortality? 
On 28 February 2019, after the occurrence of 235 deaths, the first planned 
interim analysis of OS was performed. In patients of the enzalutamide group, 
102 deaths were reported, as compared to 143 deaths in patients of the 
standard-care group (hazard ratio [HR] for death was 0.67, 95% confidence 
interval [CI] 0.52–0.86, p = 0.002). The reported results include ten addi-
tional deaths (resulting in a total of 245 deaths) after a review to ascertain 
the survival status of all patients after a median follow-up time of 34 months 
(as of 28 February 2019). In both treatment groups, the median survival 
time was not yet estimable. The Kaplan-Meier estimates of OS at three years 
were 80% in patients of the enzalutamide group (based on 94 events) and 
72% in patients of the standard-care group (based on 130 events). The effect 
of enzalutamide on OS was smaller in the following stratified subgroups: 
bone anti-resorptive therapy, planned early docetaxel treatment and high-
volume disease [4].  
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D0006: How does enzalutamide affect progression (or recurrence) of prostate 
cancer? 
In patients who received enzalutamide, PSA progression was statistically 
significantly prolonged as compared to patients of the standard-care group. 
174 events (enzalutamide group) and 333 events (standard-care group) 
were reported; the rate of event-free survival at three years was 67% and 
37%, respectively (HR 0.39, 95% CI 0.33–0.47, p < 0.001). After termination 
of the trial regimen, 113 patients of the enzalutamide group and 275 pa-
tients of the standard-care group received anti-cancer therapies [4].  
 
D0005: How does enzalutamide affect symptoms and findings (severity, fre-
quency) of prostate cancer? 
With regard to clinical PFS, 167 events were reported from the enzalutamide 
group compared to 320 events in the standard-care group. Analysis showed 
rates of event-free survival at three years of 68% in patients who received 
enzalutamide versus 41% in patients who received standard care (HR 0.40, 
95% CI 0.33–0.49, p < 0.001). Among the patients who had clinical progres-
sion, 67% (enzalutamide group) and 85% (standard-care group) of patients 
received one or more subsequent life-prolonging therapies [4]. 
 
D0011: What is the effect of enzalutamide on patients̕ body functions? 
In patients of the enzalutamide group, the occurrence of hypertension of 
grades 3 to 5 was more frequent (8%) than in patients of the standard-care 
group (4%). In each treatment group, one patient died from myocardial in-
farction and cardiac arrest, respectively. 4% of patients receiving enzalutam-
ide were affected by syncope, as compared to 1% of patients in the standard-
care group. Fatigue was more common in patients of the enzalutamide group 
(6%) than in patients receiving standard care (1%) [4].  
 
D0012: What is the effect of enzalutamide on generic health-related quality of 
life? 
D0013: What is the effect of enzalutamide on disease-specific quality of life? 
No data regarding generic HRQoL or disease-specific quality of life (QoL) is 
available yet. The authors announced the separate reporting of HRQoL-, re-
source use- and incremental cost-effectiveness-data [4]. 
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Table 1: Efficacy results of ENZAMET trial [4] 
Descriptive statistics 
and estimate variabil-
ity 
Treatment group Enzalutamide Standard care 
Number of patients 563 562 
Number of deaths at the time 
of the 1st interim analysis 
102 143 
OS, median NE NE 
Kaplan-Meier estimates of OS 
at 3 years, % 80 72 
PSA PFS, number of events 174 333 
Rate of event-free survival at 3 
years (PSA PFS), % 
67 37 
Clinical PFS, number of events 167 320 
Rate of event-free survival at 3 
years (clinical PFS), % 
68 41 
HRQoL NR NR 
Health outcomes relative to 
costs NR NR 
Effect estimate per 
comparison 
 
Comparison groups 
Enzalutamide vs.  
Standard care 
Number of deaths 
at the time of the 1st 
interim analysis 
HR for death 0.67 
95% CI 0.52–0.86 
p-value 0.002 
Rate of event-free sur-
vival at 3 years (PSA 
PFS) 
HR 0.39 
95% CI 0.33–0.47 
p-value <0.001 
Rate of event-free sur-
vival at 3 years (clinical 
PFS), % 
HR 0.40 
95% CI 0.33–0.49 
p-value <0.001 
Abbreviations: CI = confidence interval, HR = hazard ratio, HRQoL = health-related quality of life, OS = overall survival, PFS = 
progression-free survival, PSA = prostate-specific antigen, NE = not estimable, NR = not reported 
 
 
7.2.2 Safety 
C0008: How safe is enzalutamide in relation to the comparator(s)? 
AEs of grade 1 and 2 occurred in 43% of enzalutamide group patients and 
55% of standard-care group patients. The rate of AEs of grade 3 was higher 
in patients of the enzalutamide group (49%) than in patients of the stand-
ard-care group (35%). In either treatment group, 7% of patients were af-
fected by AEs of grade 4. Among patients of the enzalutamide group, six pa-
tients (1%) had a grade 5 AE; of these, two patients died from an unknown 
cause and one patient each was affected by stroke, myocardial infarction, as-
piration pneumonia and acidosis. In patients of the standard-care group, 
seven patients (1%) had an AE of grade 5; sepsis occurred in two patients, 
and one patient each was affected by cardiac arrest, sudden death from an 
unknown cause, gastric haemorrhage, urinary tract infection and sympto-
matic progression of prostate cancer. Toxic effects (especially peripheral 
neuropathy) were more frequently reported from patients of the enzalutam-
ide group who received early docetaxel [4]. 
higher rate of grade 3 
AEs in patients of 
enzalutamide group 
 
6 deaths in the 
enzalutamide group,  
7 deaths in the standard-
care group 
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Serious AEs were reported in 42% of enzalutamide group patients and in 
34% of standard-care group patients. Among the grade 3 to 5 AEs that oc-
curred in at least 2% of the patients in either group (or were selected as be-
ing events of special interest), hypertension (8%), febrile neutropenia (7%), 
neutrophil count decrease (6%) and fatigue (6%) were most frequently re-
ported in patients of the enzalutamide group as compared to febrile neutro-
penia (6%), hypertension (4%) and neutrophil count decrease (3%) in the 
standard-care group patients. Seizures occurred in seven patients (1%) of 
the enzalutamide group and in none of the standard-care group patients; six 
patients (1%) discontinued enzalutamide treatment due to the occurrence of 
seizure, one patient (<1%) discontinued enzalutamide due to clinical pro-
gression prior to the seizure event [4]. 
 
C0002: Are the harms related to dosage or frequency of applying 
enzalutamide? 
In patients of the ENZAMET trial, the mode of enzalutamide administration 
conforms to the recommended dosing regimen for the treatment of patients 
with CRPC (160 mg administered orally once daily). In case of the 
occurrence of grade ≥3 toxicities or intolerable side effects, dose 
interruption and/or dose reduction are recommended. [2]. 
According to the authors, the larger number of serious AEs among patients 
of the enzalutamide group was proportional with the longer duration of trial 
treatment: At three years, the percentage of patients who were still receiving 
a study treatment was 62% in the enzalutamide group and 34% in the 
standard-care group. The frequency of serious AEs per person-year of 
exposure to a trial regimen was similar in both treatment groups: 0.34 in 
patients of the enzalutamide group vs. 0.33 in patients of the standard-care 
group [4]. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of enzalutamide? 
There are several warnings and precautions listed with regard to the admin-
istration of enzalutamide [2, 3]: 
 The use of enzalutamide has been associated with seizure. Whilst 
the EMA suggests taking the decision to continue treatment in pa-
tients who develop seizure case by case, the FDA recommends per-
manently discontinuing enzalutamide when seizure occurs. 
 The occurrence of posterior reversible encephalopathy syndrome 
(PRES), a rare neurological disorder with rapidly evolving symp-
toms (including seizure, headache, lethargy, confusion, blindness 
and other visual and neurological disturbances, with or without as-
sociated hypertension), has been reported in patients who have re-
ceived enzalutamide. In patients who develop PRES, enzalutamide 
treatment should be discontinued. 
 In patients receiving enzalutamide, hypersensitivity reactions, in-
cluding oedema of the face, tongue or lip and pharyngeal oedema, 
have been observed. Hence, patients should be on notice of possible 
adverse reactions; if serious hypersensitivity reactions occur, en-
zalutamide should be discontinued permanently. 
higher incidence of 
serious AEs with 
enzalutamide 
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 Patients who receive enzalutamide need to be monitored for signs 
and symptoms of ischaemic heart disease; enzalutamide needs to be 
discontinued in case of grade 3–4 ischaemic heart disease. If enzalu-
tamide is prescribed to patients with a recent cardiovascular dis-
ease, it should be taken into account that patients with certain car-
diovascular diseases were excluded from several phase III studies. 
Furthermore, ADT may prolong the QT interval. 
 The occurrence of falls and fractures were reported from patients 
who received enzalutamide. Patients at risk for fractures have to be 
monitored and managed according to established treatment guide-
lines. Furthermore, the use of bone-targeted agents has to be con-
sidered. 
 The co-administration of enzalutamide with warfarin and couma-
rin-like anticoagulants should be avoided. If enzalutamide is co-
administered with an anticoagulant metabolised by CYP2C9, addi-
tional International Normalized Ratio (INR) monitoring should be 
conducted. 
 Caution is required for patients with severe renal impairment, since 
there is no data for enzalutamide treatment in this patient popula-
tion. 
 The safety and efficacy of the concomitant use of enzalutamide with 
cytotoxic, chemotherapeutical agents has not been established. Alt-
hough the co-administration of enzalutamide is deemed to have no 
clinically relevant effect on the pharmacokinetics of intravenous 
docetaxel, an increase in the occurrence of docetaxel-induced neu-
tropenia cannot be excluded. 
 In patients with rare hereditary problems of fructose intolerance, 
enzalutamide should not be administered. 
Since enzalutamide is not for use for women of childbearing potential, its 
safety and efficacy has not been established in females. However, studies in 
animals have shown reproductive toxicity. There is no evidence whether en-
zalutamide or its metabolites are present in the semen; hence, effective con-
traception is required during enzalutamide treatment and for three months 
after the last dose [2, 3].  
 
effective contraception 
required 
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Table 2: Most frequent adverse events [4] 
 
Adverse Event (according  
to NCI CTCAE version 4.02) 
 
Enzalutamide  
(n = 563) 
Standard care  
(n = 558) 
Any AE – number of patients (%) 
    Grade 1 40 (7) 77 (14) 
    Grade 2 202 (36) 230 (41) 
    Grade 3 277 (49) 194 (35) 
    Grade 4 38 (7) 40 (7) 
    Grade 5 6 (1) 7 (1) 
Serious AE 
    Number of patients (%) 235 (42) 189 (34) 
    Number of events 385 297 
    Rate during treatment exposure (95% CI) – number/year 0.34 (0.29–0.40) 0.33 (0.28–0.39) 
    AE leading to treatment discontinuation at any time –  
    number of patients 
 
33 
 
14 
Grade 3 to 5 AE – number of patients (%)* 
    Febrile neutropenia 37 (7) 32 (6) 
    Hypertension 43 (8) 25 (4) 
    Neutrophil count decreased 31 (6) 16 (3) 
    Fatigue 31 (6) 4 (1) 
    Syncope 20 (4) 6 (1) 
    Surgical or medical procedure 13 (2) 10 (2) 
    Anaemia 4 (1) 5 (1) 
    Fall 6 (1) 2 (<1) 
    Thromboembolic event 4 (1) 4 (1) 
    Acute coronary syndrome 3 (1) 4 (1) 
    Myocardial infarction 5 (1) 2 (<1) 
    Chest pain from cardiac cause 3 (1) 2 (<1) 
    Stroke 1 (<1) 2 (<1) 
    Seizure 2 (<1) 0 (0) 
    Delirium 0 (0) 1 (<1) 
Abbreviations: AE = adverse event, CI = confidence interval, CTCAE = Common Terminology Criteria for Adverse Events, 
n = number, NCI = National Cancer Institute 
* These AEs occurred in at least 2% of the patients in either group or were selected as being events of special interest. 
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7.3 Clinical effectiveness and safety –  
further studies 
ARCHES [22] is a multinational, double-blind, randomised, placebo-
controlled, phase III trial, conducted to assess the efficacy and safety of en-
zalutamide plus ADT in men with mHSPC, regardless of prior docetaxel or 
disease volume. To this end, a total of 1,150 patients were randomly as-
signed to receive either enzalutamide at a dose of 160 mg/day plus ADT (n = 
574) or placebo plus ADT (n = 576). Prior ADT and prior docetaxel (up to 
six cycles) were permitted. ARCHES trial participants had a median age of 70 
years, more than 75% of patients had an ECOG performance status of 0. The 
majority of patients were Whites; 1.4% of patients in either group were of 
African American descent. Approximately two-thirds of the trial patients had 
high-volume disease; more than 80% of patients in either group did not re-
ceive prior docetaxel chemotherapy. The median treatment duration was 
12.8 months among patients of the enzalutamide plus ADT group and 11.6 
months in patients of the placebo plus ADT group. The ARCHES trial is cur-
rently ongoing; the estimated study completion date is December 2023 [27]. 
The primary endpoint of the ARCHES trial was radiographic progression-
free survival (rPFS). Analyses showed that the risk of radiographic progres-
sion or death was statistically significantly reduced with enzalutamide plus 
ADT as compared to placebo plus ADT (HR 0.39, 95% CI 0.30–0.50, p < 
0.001). This benefit of adding enzalutamide to ADT has been observed 
across all pre-specified subgroups. Median rPFS was not reached (enzalu-
tamide plus ADT group) versus 19.0 months (placebo plus ADT group). Sta-
tistically significant improvements with enzalutamide were reported for the 
following secondary endpoints: the median time to PSA progression, the 
median time to initiation of a new antineoplastic therapy, undetectable PSA 
rate (<0.2 ng/ml), the objective response rate (ORR) and the median time to 
castration resistance. At baseline, the mean Functional Assessment of Cancer 
Therapy-Prostate (FACT-P) total score was high for both treatment groups 
and was maintained over time. 
In terms of safety, there was a high rate of AEs of all grades of approximately 
85% in both groups; most frequently reported were hot flash, fatigue and ar-
thralgia in patients receiving enzalutamide plus ADT and hot flash, fatigue 
and back pain in patients treated with placebo plus ADT. The rates of AEs of 
grade ≥3 were similar in either group: 24.3% in the enzalutamide plus ADT 
group and 25.6% in the placebo plus ADT group. Drug-related serious AEs 
were reported in 3.8% of patients (enzalutamide plus ADT group) and in 
2.8% of patients (placebo plus ADT group). The rate of AEs leading to death 
was higher in patients of the enzalutamide plus ADT group (2.4%) than in 
patients receiving placebo plus ADT (1.7%).  
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8 Estimated costs 
A0021: What is the reimbursement status of enzalutamide? 
In Austria, 112 (4x28) enzalutamide (Xtandi®) 40 mg soft capsules are avail-
able at € 2,895.35 (ex-factory price) [28]. Patients of the ENZAMET trial re-
ceived four 40 mg capsules of enzalutamide once daily, resulting in a total 
daily dose of 160 mg [4]. Based on this treatment regimen, 28 days of en-
zalutamide treatment would cost € 2,895.35.  
There was no median treatment duration reported from patients participat-
ing in the ENZAMET trial. The median follow-up time was 34 months; at 
three years, 62% of patients in the enzalutamide group were still receiving a 
trial regimen [4]. Considering this, 34 months of enzalutamide treatment 
would cost € 98,441.90. 
In addition to enzalutamide treatment, costs for testosterone suppression as 
combination therapy as primary therapy incur. If docetaxel was adminis-
tered (a decision that was left up to the individual patients and their physi-
cians), patients received docetaxel at a dose of 75 mg/m2 of body-surface ar-
ea (BSA) without prednisone or prednisolone given every three weeks for a 
maximum of six cycles [4]. Assuming an average BSA of 1.73 m2, 129.75 mg 
of docetaxel would be needed for one dose. Docetaxel (Taxotere®) 160 mg 
concentrate for solution for infusion is available at an ex-factory price of € 
1,308.12 [28], resulting in costs of € 7,848.72 for six cycles of treatment. 
Patients of the standard-care group received conventional NSAA therapy as 
chosen at the discretion of the treating clinician. Bicalutamide 50 mg daily, 
nilutamide 150 mg daily, or flutamide 250 mg three times a day were per-
mitted [20]. As an example, bicalutamide 50 mg, which is approved by the 
FDA (trade name: Casodex®) for use in combination with a LHRH analogue 
for the treatment of stage D2 metastatic carcinoma of the prostate [29] and 
which is authorised in Austria [30], is available at an ex-factory price of € 
48.27 (30 tablets á 50 mg) [28]. Here, too, costs for testosterone suppression 
and – possibly – for docetaxel treatment incur. 
 
 
9 Ongoing research 
In July 2019, a search in the databases www.clinicaltrials.gov and 
http://www.clinicaltrialsregister.eu was conducted. Currently, both phase 
III trials included in this report are ongoing: 
 ENZAMET (NCT02446405, EudraCT number: 2014-003190-42) is 
ongoing until December 2020 (estimated study completion date) 
 ARCHES (NCT02677896, EudraCT number: 2015-003869-28) is 
ongoing until December 2023 (estimated study completion date). 
NCT03246347 is a phase II trial that compares the efficacy and safety of 
ADT, docetaxel and enzalutamide compared to ADT and docetaxel. The esti-
mated study completion date is March 2027. 
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Several other phase III trials, evaluating the use of enzalutamide in metastat-
ic castration-resistant prostate cancer (mCRPC) could be identified.  
 
 
10 Discussion 
To date, the androgen-receptor inhibitor enzalutamide (Xtandi®) is neither 
approved by the EMA nor by the FDA for the addition to first-line treatment 
of patients with mHSPC.  
The aim of ENZAMET [4, 20, 21], a multinational, open-label, randomised 
phase III trial was to compare the efficacy and safety of adding enzalutamide 
to testosterone suppression. Since the trial is currently ongoing, the present-
ed data is the first interim analysis. OS was the primary endpoint of the EN-
ZAMET trial and was statistically significantly prolonged with enzalutamide 
(HR 0.67); however, the median OS time was not estimable in either treat-
ment group. The benefit in favour of enzalutamide has also been observed 
for the following secondary endpoints: PSA PFS (HR 0.39) and clinical PFS 
(HR 0.40). For two of the pre-specified endpoints, HRQoL and health out-
comes relative to costs, no results are available yet. According to the authors, 
these results will be reported separately. Among patients of the enzalutam-
ide group who have received early docetaxel, PFS was prolonged whilst OS 
was not. The incidence of serious AEs was higher among patients of the en-
zalutamide group (42%) than in patients receiving standard care (34%); fe-
brile neutropenia, hypertension and fatigue were more common in patients 
of the enzalutamide group. In patients of the enzalutamide group who re-
ceived additional early docetaxel treatment, toxic effects occurred more of-
ten than in patients of the control group. 
 
Seizures occurred in seven patients receiving enzalutamide and in none of 
the standard-care group patients. Of note, patients with a history of seizure 
or any condition that may predispose to seizure were excluded from the EN-
ZAMET trial. A direct comparison of enzalutamide to darolutamide would be 
of high interest, since darolutamide (an androgen receptor antagonist) is 
deemed to have a lower risk of inducing Central Nervous System (CNS)-
related AEs than enzalutamide [31]. 
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The efficacy and safety results of the ENZAMET study are supported by re-
cently published results of the ARCHES trial [22], assessing enzalutamide 
plus ADT compared to placebo plus ADT in men with mHSPC. Analyses 
showed that the risk of radiographic progression or death was statistically 
significantly reduced with enzalutamide plus ADT as compared to placebo 
plus ADT (HR 0.39); this benefit of adding enzalutamide to ADT has been ob-
served across all pre-specified subgroups. Median rPFS was not reached (en-
zalutamide plus ADT group) versus 19.0 months (placebo plus ADT group). 
Statistically significant improvements with enzalutamide were reported for 
the median time to PSA progression, the median time to initiation of a new 
antineoplastic therapy, undetectable PSA rate, ORR and the median time to 
castration resistance. The FACT-P total score was high for both treatment 
groups at baseline and was maintained over time. There was a high rate of 
AEs of all grades of approx. 85% in both groups; the rates of AEs of grade ≥3 
were similar in either group. Drug-related serious AEs were reported from 
3.8% of patients (enzalutamide plus ADT group) and 2.8% of patients (pla-
cebo plus ADT group); the rate of AEs leading to death was higher in patients 
of the enzalutamide plus ADT group (2.4%) than in patients receiving place-
bo plus ADT (1.7%). However, like the ENZAMET study, the ARCHES trial is 
currently ongoing and final results are not available. With regard to the ap-
plicability of ARCHES trial results, it is noteworthy that persons of African 
American descent were underrepresented.  
Since both trials investigating enzalutamide in men with mHSPC are current-
ly ongoing and interim analysis data were presented, final results are urgent-
ly required. The median follow-up time in the ENZAMET trial was 34 
months; hence, long-term results are needed to assess the efficacy and safety 
of enzalutamide for this indication. Furthermore, HRQoL results are required 
to determine the clinical benefit of enzalutamide treatment. 
An important issue to discuss is the choice of the appropriate treatment for 
the individual patient. Considering the range of available treatment options 
for men with mHSPC, including docetaxel, abiraterone acetate, apalutamide 
and enzalutamide (of note, the last two have not been approved yet for the 
treatment of mHSPC), it might be challenging to determine the appropriate 
therapy. In this regard, the identification of novel biomarkers that may guide 
precision medicine in the near future [32] may play an important role. Fur-
thermore, randomised, comparative studies with consistent inclusion crite-
ria are required to assess which patients benefit the most from the respec-
tive therapy. The final decision on the applied therapy is likely to depend on 
the individual safety profile of docetaxel, abiraterone and enzalutamide, re-
spectively. 
The ENZAMET trial was conducted as an open-label study. Thus, patients 
and clinicians knew about the intervention; however, there is no information 
available whether the assessors were blinded or not. In the course of the 
ENZAMET trial, 1,125 patients were treated in 83 centres. This fact suggests 
that only a small number of patients were treated in each centre, leading to a 
high susceptibility for bias. The generation of randomisation sequence as 
well as allocation concealment was adequate. Reasons for discontinuations 
were reported. Since the trial is currently ongoing, only data from the first 
interim analysis is available; final analysis data is lacking. For two of the pre-
specified endpoints – HRQoL and health outcomes relative to costs – results 
are not available yet and will be presented separately as announced by the 
authors. An aspect that increases the risk of bias was the funding of EN-
ZAMET by the manufacturer. Overall, a high risk of bias – mainly due to the 
ARCHES trial: risk of 
radiographic 
progression or death 
statistically significantly 
reduced with 
enzalutamide + ADT 
 
 
 
 
 
 
 
rate of AEs leading to 
death higher with 
enzalutamide + ADT 
 
ARCHES is ongoing, 
final results are lacking 
ENZAMET and ARCHES: 
final analysis data + 
long-term results 
required 
how to determine the 
optimal treatment for 
the individual patient? 
high risk of bias 
 
 
 
 
 
 
 
 
 
 
limited applicability  
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lack of blinding – was detected. Patients with a significant cardiovascular 
disease within the last three months, including myocardial infarction, unsta-
ble angina, congestive heart failure, ongoing arrhythmias of Grade > 2 or 
thromboembolic events, were excluded from the ENZAMET trial. Although 
the median age at diagnosis of metastatic prostate cancer is 71 years, the ap-
plicability of results might be limited. There is a higher incidence of prostate 
cancer in African Americans; since no information on the ethnic groups of 
ENZAMET trial participants is available, the applicability of study results is 
unclear in this regard. 
Given the non-curative setting of enzalutamide and the statistically signifi-
cant primary endpoint OS, we applied form 2a of the ESMO-MCBS in order to 
assess whether enzalutamide satisfies the criteria for a “meaningful clinical 
benefit” (score 4 or 5) [19]. However, since neither median OS nor PFS were 
estimable for the enzalutamide group, no score calculations could be applied. 
Based on the treatment regimen of the ENZAMET trial, costs for 28 days of 
enzalutamide treatment are € 2,895.35 [28]. The median follow-up time was 
34 months; at three years, 62% of patients in the enzalutamide group were 
still receiving a trial regimen [4]. 34 months of enzalutamide treatment 
would cost € 98,441.90. In addition to enzalutamide treatment, costs for tes-
tosterone suppression as background therapy incur and – if requested – also 
for docetaxel (€ 7,848.72 for six cycles of treatment). For comparison, con-
ventional NSAA therapy with bicalutamide (50 mg daily) would result in 
monthly costs of  € 48.27 (30 tablets á 50 mg) [28]. Here, too, costs for tes-
tosterone suppression and for optional docetaxel treatment incur. 
Recently published results from the ENZAMET trial indicate that patients 
with mHSPC benefit from the addition of enzalutamide to standard first-line 
treatment in terms of OS and PSA PFS. However, the administration of en-
zalutamide was associated with a higher rate of serious AEs as compared to 
standard care. Due to the ongoing status of the trial, mature final and long-
term data are lacking. However, due to the nature of the open-label study de-
sign, a high risk of bias is existent and will remain even with mature data. 
Since final OS data and HRQoL data are not available yet, the clinical benefit 
for affected patients cannot be assessed. More mature data, acquired over 
longer treatment duration, are required to prove the present results. 
 
 
ESMO-MCBS 
evaluations were not 
applicable due to lack of 
median OS and PFS data 
28 days of enzalutamide 
treatment = € 2,895.35 
 
additional costs for 
testosterone 
suppression and 
optional docetaxel 
therapy 
benefit with 
enzalutamide, but 
higher rate of serious 
AEs 
 
mature data required to 
determine the clinical 
benefit  
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [25, 26] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
Enzalutamide mHSPC NC OS 2a - - - - - - - - NA3 
Original 
ESMO-
MCBS 
Enzalutamide mHSPC NC OS 2a - - - - - - - - NA3 
Abbreviations: AJ = Adjustments, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, mHSPC = metastatic hormone-sensitive prostate 
cancer, NA = not applicable, OS = overall survival, PE = primary endpoint, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint of 
interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the ex-
act same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically favours 
drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and outcomes 
that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjustments 
separately. 
 
                                                                        
3 An ESMO-MCBS score cannot be assessed, since none of the available study endpoints were applicable for an evaluation. 
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12 Appendix  
 
Table 4: Administration and dosing of enzalutamide (Xtandi®) [3, 20]  
 Technology Comparator 
Administration mode 
Enzalutamide (Xtandi®) is provided as 40 
mg soft gelatine capsules administered as 
160 mg (4 capsules) orally once daily. The 
tablets should not be cut, crushed or 
chewed, but should be swallowed whole 
with water, and can be taken with or with-
out food. 
Patients of the control group receive a 
conventional NSAA, i.e., bicalutamide 50 
mg daily, nilutamide 150 mg daily, or 
flutamide 250 mg three times a day. The 
choice of NSAA is at the discretion of the 
treating clinician. Drug administration 
should be according to the product infor-
mation guide. Cyproterone is not permit-
ted. 
Description of packaging 
Soft capsule. White to off-white oblong soft 
capsules (approximately 20 mm x 9 mm) 
imprinted with “ENZ” in black ink on one 
side. Each soft capsule contains 40 mg of 
enzalutamide. 
- 
Total volume contained in packag-
ing for sale 
40 mg film-coated tablets: Cardboard wallet 
incorporating a PVC/PCTFE/aluminium blis-
ter of 28 film-coated tablets. Each carton 
contains 112 film-coated tablets (4 wallets). 
- 
Dosing 
The recommended dose for adult men with 
metastatic/non-metastatic CRPC is 160 mg 
enzalutamide (four 40 mg soft capsules) as 
a single oral daily dose. 
Dosing according to the respective prod-
uct information guide. 
Median treatment duration Not reported. Not reported. 
Contraindications 
Hypersensitivity to the active substance(s) 
or to any of the excipients: 
 Capsule contents: caprylocaproyl 
macrogol-8 glycerides, butylhy-
droxyanisole (E320) , butylhy-
droxytoluene (E321) 
 Capsule shell: gelatin, sorbitol 
sorbitan solution, glycerol, titani-
um dioxide (E171), purified water  
 Printing ink: iron oxide black 
(E172), Polyvinyl acetate 
phthalate 
According to the respective product in-
formation guide. 
Drug interactions 
Potential for other medicinal products to af-
fect enzalutamide exposures: CYP2C8 inhibi-
tors, CYP3A4 inhibitors, CYP2C8 and CYP3A4 
inducers. 
Potential for enzalutamide to affect expo-
sures to other medicinal products: enzyme 
induction, CYP1A2 and CYP2C8 substrates, P-
gp substrates, BCRP, MRP2, OAT3 and OCT1 
substrates, medicinal products which pro-
long the QT interval. 
Effect of food on enzalutamide exposures: 
no clinically significant effect on the extent 
of exposure to enzalutamide. 
According to the respective product in-
formation guide. 
Abbreviations: CRPC = castration-resistant prostate cancer, NSAA = non-steroidal anti-androgen  
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Table 5: Characteristics of ENZAMET trial  
Title: Enzalutamide with standard first-line therapy in metastatic prostate cancer [4, 20, 21] 
Study identifier NCT02446405, EudraCT number: 2014-003190-42, ANZCTR number: ACTRN12614000110684 
Design Multinational, open-label, randomised, phase 3 trial 
Duration of main phase: Assignment to treatment groups: from March 2014 
through March 2017 
Date of the first interim analysis of the primary endpoint: 
28 February 2019 
Median follow-up: 34 months 
Hypothesis Superiority 
Funding Funded by Astellas Scientific and Medical Affairs and others. 
Treatment groups 
 
Intervention (n = 563) 
Patients received enzalutamide provided as 40 mg soft 
gelatine capsules administered as 160 mg (4 capsules) oral-
ly once daily until clinical disease progression or prohibi-
tive toxicity. 
Control (n = 562) 
Patients of the control group will receive a conventional 
NSAA, i.e., bicalutamide 50 mg daily, nilutamide 150 mg 
daily, or flutamide 250 mg three times a day. The choice of 
NSAA is at the discretion of the treating clinician. Drug 
administration should be according to the product infor-
mation guide. 
Endpoints and definitions 
 
Overall survival 
(primary end-
point) 
 
OS Defined as the interval from the date of randomisation to 
date of death from any cause, or the date of last known 
follow-up alive. 
PSA progression-
free survival (sec-
ondary endpoint) 
PSA PFS 
PSA PFS is defined as the interval from the date of ran-
domisation to the date of first evidence of PSA progres-
sion, clinical progression, or death from any cause, which-
ever occurs first, or the date of last known follow-up 
without PSA progression. 
PSA progression is defined as: a rise in PSA by more than 
25% and more than 2ng/mL above the nadir (lowest PSA 
point). This needs to be confirmed by a repeat PSA per-
formed at least 3 weeks later.  
Clinical progres-
sion-free survival 
(secondary end-
point) 
Clinical PFS 
Clinical PFS is defined as the interval from the date of ran-
domisation to the date of first clinical evidence of disease 
progression or death from any cause, whichever occurs 
first, or the date of last known follow-up without clinical 
progression. Clinical progression is defined by progression 
on imaging, development of symptoms attributable to 
cancer progression, or initiation of other anti-cancer 
treatment for prostate cancer. 
Health-related 
quality of life 
(secondary end-
point) 
HRQoL - 
Health outcomes 
relative to costs 
(secondary end-
point) 
- 
Information on the following areas of health-care resource 
usage will be collected: hospitalisations, visits to health 
professionals, and medications. Australian unit costs will 
be applied to the resource usage data to estimate the in-
cremental cost of the addition of enzalutamide to stand-
ard treatment. 
Database lock NR 
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Title: Enzalutamide with standard first-line therapy in metastatic prostate cancer [4, 20, 21] 
Study identifier NCT02446405, EudraCT number: 2014-003190-42, ANZCTR number: ACTRN12614000110684 
Results and analysis  
Analysis description Primary Analysis 
It was determined that the enrolment of 1,100 patients (with 470 deaths) would provide a power of 
at least 80% to detect a 25% lower hazard of death in the enzalutamide group than in the stand-
ard-care group (HR 0.75), with a two-sided type I error rate of 0.05. In these calculations, a 3-year 
survival rate of 65% in the standard-care group on the basis of two previous studies of enzalutam-
ide in men with metastatic CRPC was assumed. Protocol versions 1 and 2 called for an interim analy-
sis of OS after the occurrence of 67% of the pre-specified 470 deaths with the use of the Lan–
DeMets alpha-spending function. Protocol version 3, which was written after external evidence, be-
came available for improved OS with early abiraterone treatment, added interim analyses of OS af-
ter the occurrence of 50% and 80% of the pre-specified 470 deaths. The trial executive committee 
made these decisions without any knowledge of outcomes in each treatment group.  
Efficacy analyses were based on the ITT principle and included all the patients who had undergone 
randomisation. The relevant follow-up times of patients who did not have an event were included 
in time-to-event analysis as censored observations. These analyses included patients who were lost 
to follow-up or who withdrew consent for continued follow-up after the date of consent with-
drawal. Patients who had undergone randomisation and received a dose of any trial drug were in-
cluded in analyses of drug exposure and safety. The Kaplan–Meier method was used to summarise 
time-to-event endpoints and to calculate event probabilities at 3 years. An unadjusted log-rank test 
was used for the primary comparison of randomly assigned trial groups. Cox proportional-hazards 
regression was used to estimate HRs, their 95% CIs, and interactions between group assignment 
and pre-specified baseline characteristics. The proportional-hazards assumption was tested. All P 
values and CIs are two-sided. 
It was pre-specified that consistency of the treatment effect would be evaluated across the follow-
ing subgroups: Gleason score (≤  7 vs. 8 to 10); age at trial entry (< 70 years or ≥  70 years); ECOG 
performance status score (0 vs. 1 or 2); the presence or absence of visceral metastases in the lung, 
liver, or other organs; volume of disease (high or low); planned use or non-use of early docetaxel 
treatment; planned use or non-use of bone anti-resorptive therapy; the ACE-27 comorbidity score 
(0 or 1 vs. 2 or 3); prior local treatment (radiation, surgery, or neither); and geographic region (Aus-
tralia or New Zealand vs. North America vs. Ireland or United Kingdom). It was pre-specified that 
the effects of enzalutamide according to the volume of disease and the use of early docetaxel 
treatment were of particular interest. The Benjamini–Hochberg method was used to account for 
multiple comparisons associated with subgroup analyses. 
Analysis population  Inclusion 
 Male aged 18 or older with metastatic adenocarcinoma of the prostate 
defined by 
- documented histopathology or cytopathology of prostate adeno-
carcinoma from a biopsy of a metastatic site or 
- documented histopathology of prostate adenocarcinoma from a 
TRUS biopsy, radical prostatectomy, or TURP and metastatic dis-
ease consistent with prostate cancer or 
- metastatic disease typical of prostate cancer (i.e., involving bone 
or pelvic lymph nodes or para-aortic lymph nodes) and a serum 
concentration of PSA that is rising and > 20ng/mL. 
 Target or non-target lesions according to RECIST 1.1 
 Adequate bone marrow function: Hb ≥  100g/L and WCC ≥  4.0 x 109/L 
and platelets ≥ 100 x 109/L. 
 Adequate liver function: ALT <2 x ULN and bilirubin < 1.5 x ULN, (or if 
bilirubin is between 1.5-2x ULN, they must have a normal conjugated bil-
irubin). If liver metastases are present ALT must be <5xULN. 
 Adequate renal function: calculated creatinine clearance > 30 ml/min 
(Cockcroft-Gault) 
 ECOG performance status of 0-2. Patients with performance status 2 are 
only eligible if the decline in performance status is due to metastatic 
prostate cancer. 
 Study treatment both planned and able to start within 7 days after ran-
domisation 
 Willing and able to comply with all study requirements, including treat-
ment and required assessments 
 Completed baseline HRQoL questionnaires unless unable to complete 
because of limited literacy or vision 
 Signed, written, informed consent. 
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Title: Enzalutamide with standard first-line therapy in metastatic prostate cancer [4, 20, 21] 
Study identifier NCT02446405, EudraCT number: 2014-003190-42, ANZCTR number: ACTRN12614000110684 
 
Exclusion 
 Prostate cancer with significant sarcomatoid or spindle cell or neuroen-
docrine small cell components 
 History of: 
- seizure or any condition that may predispose to seizure (e.g., prior 
cortical stroke or significant brain trauma) 
- loss of consciousness or transient ischemic attack within 12 months 
of randomisation 
- significant cardiovascular disease within the last 3 months includ-
ing: myocardial infarction, unstable angina, congestive heart fail-
ure (NYHA functional capacity class II or greater, ongoing ar-
rhythmias of grade > 2 (NCI CTCAE, version 4.03), thromboembol-
ic events (e.g., deep vein thrombosis, pulmonary embolism). 
Chronic stable atrial fibrillation on stable anticoagulant therapy is 
allowed. 
 Life expectancy of less than 12 months 
 History of another malignancy within 5 years prior to randomisation, ex-
cept for either non-melanomatous carcinoma of the skin or, adequately 
treated, non-muscle-invasive urothelial carcinoma of the bladder (Tis, Ta 
and low grade T1 tumours) 
 Concurrent illness, including severe infection that might jeopardise the 
ability of the patient to undergo the procedures outlined in this protocol 
with reasonable safety (HIV-infection is not an exclusion criterion if it is 
controlled with anti-retroviral drugs that are unaffected by concomitant 
enzalutamide) 
 Presence of any psychological, familial, sociological or geographical con-
dition potentially hampering compliance with the study protocol and 
follow-up schedule, including alcohol dependence or drug abuse 
 Patients who are sexually active and not willing/able to use medically ac-
ceptable forms of barrier contraception 
 Prior ADT for prostate cancer (including bilateral orchidectomy), except 
in the following settings: 
- Started less than 12 weeks prior to randomisation and PSA is stable 
or falling. The 12 weeks starts from whichever of the following oc-
curs earliest: first dose of oral anti-androgen, LHRHa, or surgical 
castration. 
- In the adjuvant setting, where the completion of adjuvant hormo-
nal therapy was more than 12 months prior to randomisation and 
the total duration of hormonal treatment did not exceed 24 
months. For depot preparations, hormonal therapy is deemed to 
have started with the first dose and to have been completed when 
the next dose would otherwise have been due, e.g., 12 weeks after 
the last dose of depot goserelin 10.8 mg 
 Participation in other clinical trials of investigational agents for the 
treatment of prostate cancer or other diseases. 
Characteristics Intervention n = 563 
Control 
n = 562 
Mean age, years 
Median age (IQR), years  
68.9 ± 8.1 
69.2 (63.2–74.5) 
68.8 ± 8.3 
69.0 (63.6–74.5) 
Region, n (%) 
   Australia 
   Canada 
   Ireland 
   New Zealand 
   United Kingdom 
   United States 
 
324 (58) 
97 (17) 
39 (7) 
20 (4) 
63 (11) 
20 (4) 
 
321 (57) 
107 (19) 
43 (8) 
19 (3) 
50 (9) 
22 (4) 
Planned use of early docetaxel, n (%) 254 (45) 249 (44) 
Volume of disease, n (%) 
   High 
   Low 
 
291 (52) 
272 (48) 
 
297 (53) 
265 (47) 
Visceral metastases, n (%) 62 (11) 67 (12) 
Number of months since diagnosis of metas-
tasis 
   Mean 
   Median (IQR) 
 
 
2.9 ± 6.9 
1.9 (0.9–2.8) 
 
 
3.1 ± 7.2 
1.9 (1.0–2.8) 
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Title: Enzalutamide with standard first-line therapy in metastatic prostate cancer [4, 20, 21] 
Study identifier NCT02446405, EudraCT number: 2014-003190-42, ANZCTR number: ACTRN12614000110684 
Gleason score, n (%) 
    ≤7 
   8-10 
   Missing data 
 
152 (27) 
335 (60) 
76 (13) 
 
163 (29) 
321 (57) 
78 (14) 
Previous therapy, n (%) 
   Adjuvant ADT 
   Anti-androgen therapy 
   LHRHa 
   Bilateral orchiectomy 
   Docetaxel 
 
58 (10) 
285 (51) 
411 (73) 
5 (1) 
95 (17) 
 
40 (7) 
316 (56) 
418 (74) 
8 (1) 
83 (15) 
Applicability of evidence 
Population 
There is no information on the ethnic groups of the ENZAMET trial participants. Since there is a 
higher incidence of prostate cancer in African Americans than in other ethnic groups, the applicabil-
ity of results in this regard is unclear.  
Patients with a significant cardiovascular disease within the last 3 months including myocardial in-
farction, unstable angina, congestive heart failure, ongoing arrhythmias of grade > 2 and thrombo-
embolic events were excluded from the ENZAMET trial. Since the trial was conducted in elderly pa-
tients (median age of participant was 69 years), the applicability of results might be limited. 
Intervention 
To date, enzalutamide is not approved for the assessed indication. However, the dosing regimen of 
enzalutamide in ENZAMET trial patients was consistent with the administration in patients with 
CRPC, an indication that is already licensed. No issue regarding intervention applicability was iden-
tified. 
Comparators 
In the ENZAMET trial, conventional NSAAs (including bicalutamide, flutamide and nilutamide) 
were chosen as comparators. Since this intervention is no longer the standard of care, the chosen 
comparator is considered to be inappropriate. 
Outcomes 
There is evidence that the addition of enzalutamide to standard first-line therapy in patients with 
mHSPC is associated with an improvement in PFS and OS. Since the ENZAMET trial is ongoing and 
first interim data was presented, final results for all endpoints are lacking. Hence, the applicability 
of outcomes cannot be assessed yet. 
Setting 
ENZAMET is an international trial, conducted in 83 centres across Australia, New Zealand, Canada, 
the United Kingdom and Ireland. There was no information found regarding the ethnicity of the 
participants. No issue regarding setting applicability was found. 
Abbreviations: ADT = androgen deprivation therapy, ALT = alanine aminotransferase, ANZCTR = Australian New Zealand Clinical Trials 
Registry, CI = confidence interval, CRPC = castration-resistant prostate cancer, CTCAE = Common Terminology Criteria for Adverse 
Events, ECOG = Eastern Cooperative Oncology Group, Hb = haemoglobin, HIV = human immunodeficiency virus, HR = hazard ratio, 
HRQoL = health-related quality of life, ITT = intention-to-treat, IQR = interquartile range, LHRHa = luteinizing hormone releasing hor-
mone analogue, n = number, NCI = National Cancer Institute, NR = not reported, NSAA = non-steroidal anti-androgen, NYHA = New 
York Heart Association, OS = overall survival, PFS = progression-free survival, PSA = prostate-specific antigen, RECIST = Response 
Evaluation Criteria In Solid Tumors, TRUS = transrectal ultrasound guided, TURP = transurethral resection of the prostate, ULN = upper 
limit normal, WCC = white cell count 
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Table 6: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [4, 20, 23] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: Central randomisation system yes 
Adequate allocation concealment: Following randomisation, participants will be allocated to receive 
either enzalutamide or NSAA in addition to their LHRHa (or surgical castration) via a central ran-
domisation system that stratifies for volume of disease, site, co-morbidities and use of anti-resorptive 
therapy – denosumab, zoledronic acid or neither at time of starting ADT. 
yes 
Blinding: 
open-label 
Patient: Unblinded no 
Treating physician: Unblinded no 
Selective outcome reporting unlikely: The ENZAMET trial is currently ongoing; hence, only data from 
the first interim analysis is available. Final analysis data is lacking. There is no data available for two 
pre-specified endpoints (HRQoL and health outcomes relative to costs); according to the authors, 
these results will be reported separately. Reasons for discontinuations have been reported. 
unclear 
No other aspects which increase the risk of bias: The trial was funded by Astellas Scientific and Medi-
cal Affairs and others. Astellas Pharma provided enzalutamide and financial support for trial conduct; 
representatives of the manufacturer reviewed drafts of the protocol and trial report, but were not 
otherwise involved in any aspects of the trial design, data accrual, data analysis, or manuscript prepa-
ration. 
no 
Risk of bias – study level high  
Abbreviations: ADT = androgen deprivation therapy, HRQoL = health-related quality of life, LHRH = luteinizing hormone releasing hormone 
analogue, NSAA = non-steroidal anti-androgen 
 
